Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 2, 2010, Pages 92-103

  Mercer, Kelly E ^a   Apostolov, Eugene O ^b   da Costa, Goncalo Gamboa ^c   Yu, Xinfeng ^a   Lang, Patrick ^a   Roberts, Dean W ^a   Davis, Warren ^d   Basnakian, Alexei G ^b   Kadlubar, Fred F ^a   Kadlubar, Susan A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Genotype; SULT1A1; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CASPASE; ENDONUCLEASE G; ESTROGEN RECEPTOR; SULFOTRANSFERASE 1A1; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SULFATION; PROTEIN EXPRESSION;

EID: 77954630330     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP and De-Mets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-856.
2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
4. Bardou VJ, Arpino G, Elledge RM, Osborne CK and Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-1979.
5. Borges HL and Linden R. Gamma irradiation leads to two waves of apoptosis in distinct cell populations of the retina of newborn rats. J Cell Sci 1999; 112 (Pt 23): 4315-4324.
6. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA and Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121.
7. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA and Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
8. Falany CN, Wheeler J, Oh TS and Falany JL. Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 1994; 48: 369-375.
9. Adjei AA and Weinshilboum RM. Catecholestrogen sulfation: possible role in carcinogenesis. Biochem Biophys Res Commun 2002; 292: 402-408.
10. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA and Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997; 239: 298-304.
11. Ozawa S, Tang YM, Yamazoe Y, Kato R, Lang NP and Kadlubar FF. Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact 1998; 109: 237-248.
12. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF and Ambrosone CB. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002; 94: 1635-1640.
13. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE and Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7: R284-290.
14. Basnakian AG, Apostolov EO, Yin X, Abiri SO, Stewart AG, Singh AB and Shah SV. Endonuclease G promotes cell death of non-invasive human breast cancer cells. Exp Cell Res 2006; 312: 4139-4149.
15. Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim do H, Kwon JK, Park SE, Park JH, Cho HR, Lee SH, Park SK, Lee BJ, Min YJ and Park JW. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspaseindependent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer 2008; 122: 672-680.
16. Wang X, Tryndyak V, Apostolov EO, Yin X, Shah SV, Pogribny IP and Basnakian AG. Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation. Cancer Lett 2008; 270: 132-143.
17. Beland FA, Churchwell MI, Hewer A, Phillips DH, da Costa GG and Marques MM. Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling. Biochem Biophys Res Commun 2004; 320: 297-302.
18. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R and Sheehan DM. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 2000; 54: 138-153.
19. Tolleson WH, Doerge DR, Churchwell MI, Marques MM and Roberts DW. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J Agric Food Chem 2002; 50: 4783-4790.
20. Frame LT, Ozawa S, Nowell SA, Chou HC, DeLongchamp RR, Doerge DR, Lang NP and Kadlubar FF. A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab Dispos 2000; 28: 1063-1068.
21. Williams LD, Twaddle NC, Churchwell MI and Doerge DR. Quantification of tamoxifen and metabolites and soy isoflavones in human plasma using liquid chromatography with electrospray ionization tandem mass spectrometry. J AOAC Int 2006; 89: 1168-1173.
22. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA and Skaar TC. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-159.
23. Nowell S and Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 2006; 25: 1673-1678.
24. Falany JL and Falany CN. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 1996; 56: 1551-1555.
25. Mandlekar S and Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6: 469-477.
26. Obrero M, Yu DV and Shapiro DJ. Estrogen receptor-dependent and estrogen receptorindependent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002; 277: 45695-45703.
27. Janicke RU, Sprengart ML, Wati MR and Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357-9360.
28. Numazawa M, Tominaga T, Watari Y and Tada Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006; 71: 371-379.
29. Purohit A, Williams GJ, Howarth NM, Potter BV and Reed MJ. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-Osulfamate. Biochemistry 1995; 34: 11508-11514.
30. Longcope C. Metabolism of dehydroepiandrosterone. Ann N Y Acad Sci 1995; 774: 143-148.
31. Daniel P, Gaskell SJ, Bishop H, Campbell C and Nicholson RI. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 1981; 17: 1183-1189.
32. Lien EA, Wester K, Lonning PE, Solheim E and Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 1991; 63: 641-645.
33. MacCallum J, Cummings J, Dixon JM and Miller WR. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000; 82: 1629-1635.
34. Krieser RJ and Eastman A. The cloning and expression of human deoxyribonuclease II. A possible role in apoptosis. J Biol Chem 1998; 273: 30909-30914.
35. Li LY, Luo X and Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001; 412: 95-99.
36. Yin X, Apostolov EO, Shah SV, Wang X, Bogdanov KV, Buzder T, Stewart AG and Basnakian AG. Induction of renal endonuclease G by cisplatin is reduced in DNase I-deficient mice. J Am Soc Nephrol 2007; 18: 2544-2553.
37. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF and Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.